Welcome to our dedicated page for Alterity Therapeutics news (Ticker: ATHE), a resource for investors and traders seeking the latest updates and insights on Alterity Therapeutics stock.
News and updates for Alterity Therapeutics Limited (ATHE) center on its progress as a clinical stage biotechnology company developing disease modifying treatments for neurodegenerative diseases. The company’s announcements emphasize its initial focus on Parkinson’s disease and related disorders, particularly Multiple System Atrophy (MSA), and the development of its lead oral agent ATH434.
Investors and followers of ATHE can expect regular news about clinical trial milestones and data presentations. Alterity has reported positive results from its ATH434‑201 randomized, double‑blind, placebo‑controlled Phase 2 trial in MSA, as well as topline data from the ATH434‑202 open‑label Phase 2 trial in more advanced MSA. Company news often highlights analyses of UMSARS Part I activities of daily living scores, orthostatic hypotension symptom assessments, wearable sensor data, and neuroimaging and biomarker endpoints such as brain iron and the MSA Atrophy Index.
Alterity’s news flow also includes regulatory and designation updates, such as Fast Track Designation by the U.S. Food and Drug Administration and Orphan Drug Designation by the FDA and European Commission for ATH434 in MSA. Additional items cover participation in major neurology and movement disorder conferences, where the company presents new analyses, biomarker findings, and natural history study results, as well as appearances at healthcare and biotech investor events.
On this page, readers can follow announcements about capital raises, quarterly cash flow reports, and corporate presentations that describe Alterity’s cash position, development plans, and engagement with regulators. For those tracking ATHE, the news stream provides context on how the company is advancing ATH434 in MSA, refining its biomarker strategy, and interacting with the scientific and investment communities over time.
Alterity Therapeutics Limited (NASDAQ: ATHE) announced positive developments regarding its lead compound ATH434, receiving FDA guidance for its clinical development, including agreement on the Phase 2 study design. The company reported a cash balance of $9.2M, bolstered by an additional $1.5M from a recent share issuance. Furthermore, Alterity has resolved its previous compliance issue with NASDAQ regarding the minimum bid price requirement, confirming re-compliance.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced a successful pre-IND meeting with the FDA regarding its lead compound, ATH434, for treating Multiple System Atrophy (MSA). Following a Phase 1 clinical trial, the FDA provided guidance on the Phase 2 study design, including safety monitoring and patient population. Importantly, there are no approved treatments for MSA, prompting collaboration with the FDA to establish appropriate efficacy endpoints. The company will also conduct a natural history study called bioMUSE to better track disease progression.